A dual-functional cobalt ferrite nanocomplex for targeted cisplatin prodrug delivery and MALAT1 gene silencing in gastric cancer cells Authors: Fatemeh Doryani, Amirhossein Ahmadi, Hossein Nikmanesh, Fatemeh Azami, Ahmad Ghasemi Published: 2025 ABSTRACT Cisplatin (CDDP) is a common drug for gastric cancer (GC) treatment. The aberrant expression of MALAT-1, a long noncoding RNA, plays a critical role in CDDP resistance. Thus, silencing MALAT-1 using short hairpin RNAs (shRNA) can be an effective way to overcome CDDP resistance. The present study aims to use magnetic cobalt ferrite nanoparticles (CoFe2O4), functionalized with polyethyleneimine and chitosan, as targeted carriers for delivering Pt(IV)-COOH prodrug and shRNA-expressing cassettes to AGS cells. The shRNA-expressing cassettes were synthesized by PCR. Functionalized CoFe₂O₄ nanoparticles were synthesized, and their morphology, structural, and magnetic properties were evaluated using FESEM, EDAX, HRTEM, XRD, FT-IR, VSM and Zeta potential analyzer. The delivery of shRNA to AGS cells was evaluated using fluorescent microscopy. The efficiency of MALAT-1 gene silencing was quantified by qPCR. Additionally, cell viability, migration, and apoptosis induction were assessed using MTT, wound healing, and caspase 3/7 activity assays, respectively. The results showed the zeta potential of + 15.98 mV with PDI of 0.034. The cell uptake efficiency was 89% which led to a 9-fold decrease in MALAT-1 expression. Furthermore, these nanoparticles significantly reduced cell viability and migration while increasing caspase 3/7 activity (p < 0.05). This study demonstrated the efficacy of functionalized cobalt ferrite nanocomplexes for drug and gene therapy in vitro, but this needs to be confirmed in an in vivo study.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-32555-0. Introduction Gastric cancer (GC) represents a prevalent and often fatal disease, ranking as the fifth most common cancer and the fourth leading cause of global mortality in 20201,2. Despite advancements in early detection and novel therapeutic modalities enhancing the overall prognosis for individuals with GC, the disease remains a formidable challenge. In cases of metastatic GC, the average overall survival is typically less than one year, with a 5-year survival rate of around 20%3,4. Chemotherapy is a pivotal treatment strategy for advanced and metastatic stages of GC; however, developing drug resistance among GC cells poses a significant hurdle to successful treatment. In addition to the challenge of drug resistance, the administration of chemotherapeutic agents may exert substantial toxicity on healthy tissues, leading to a range of adverse side effects5. Cisplatin (CDDP) or Pt(II) is a primary chemotherapy agent in GC treatment regimens and a potent therapeutic in combating malignant gastric tumors. CDDP functions by inducing DNA bulky lesions, blocking DNA replication, and inducing apoptosis. Nevertheless, due to its potential neurotoxic and nephrotoxic effects, the clinical utility of cisplatin is limited. To overcome this challenge, administration of cisplatin prodrugs like Pt(IV)-COOH decreases CDDP adverse effects, as it is more stable in plasma and converts to Pt(II) under the activity of reducing agents in cytoplasm after entering cells6. However, developing cisplatin resistance is another challenge that further complicates patient treatment outcomes and ultimately results in GC treatment failure7. Multiple proteins and signaling pathways and dysregulation of gene expression networks are involved in CDDP resistance8. Aberrant expression of lncRNAs, noncoding RNAs longer than 200 nucleotides, plays a critical role in CDDP resistance9. Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1), an 8.5-kb lncRNA gene located on human chromosome 11q13, is one of the non-coding RNAs whose overexpression in cancer cells associates with CDDP resistance via PI3K/AKT pathway activation10, promoting autophagy11, blocking apoptosis, upregulation of drug efflux pumps activities, enhancing DNA repair ability, potentiating the stemness of cancer cells, promoting epithelial-mesenchymal transition and cell cycle progression12. Interestingly, the downregulation of MALAT1 via small interfering RNAs (siRNAs) decreases the CDDP resistance in GC10. siRNAs are double-stranded RNAs with 20 to 24 nucleotide lengths which are processed in cells such that one strand incorporates into the RNA-induced silencing (RISC) complexes, which ultimately bind to its target mRNA and result in silencing of target gene expression13. siRNAs can be directly transferred to cells or transcribed from its coding gene, short hairpin RNA (shRNA)14. The shRNA gene can be generated by polymerase chain reaction (PCR) and either cloned in an expression plasmid or used as a PCR product consisting of a promoter and downstream shRNA gene15. To address the challenge of chemoresistance, researchers are increasingly exploring the combination of CDDP with siRNAs or shRNAs in a combination therapy approach16. Consequently, the prospect of alleviating cisplatin’s side effects and enhancing its efficacy by developing drug carriers, including nanoparticles, that deliver cisplatin to the tumor site and silencing MALAT1 expression emerges as a promising avenue for a therapeutic approach for GC. Recent therapeutic innovations have underscored the potential of nanotechnology, particularly nanoparticle-based approaches, in addressing cancer treatment challenges. Nanoparticle-based designs offer distinct advantages compared to conventional anticancer methods, exhibiting improved targeting specificity and enhanced drug delivery with superior bioavailability17,18. Among the array of nanotherapeutic strategies, the utilization of magnetic nanoparticles (MNP) has garnered attention for their high targeting and transport efficiency using an external magnetic field, low toxicity, controlled size, and biodegradability, thereby mitigating the limitations associated with conventional cancer chemotherapy19,20. CoFe2O4 nanoparticles are among MNPs in which Co2+ ions are placed on octahedral sites, but Fe3+ ions are located in both tetrahedral and octahedral sites21. CoFe2O4 MNPs are at the center of attention in drug delivery due to their characteristics, including thermal and chemical stability, moderate saturation magnetization, and large coercivity, which make these MNPs candidate carriers to deliver drugs to target sites21. Despite these advantages, CoFe2O4 MNPs can be toxic, have low drug loading capacity, and aggregate rapidly; they must be coated with biocompatible polymers. Therefore, different types of polymers like polyethyleneimine (PEI) and Chitosan can be used to coat the magnetic core to improve its drug/gene loading capacity, chemical stability, and biocompatibility22–24. In this context, the present research delves into the development of a magnetic nano drug delivery system consisting of a CoFe2O4 core coated by PEI and Chitosan and conjugated with (Pt(IV)- COOH) and anti-MALAT1 shRNA gene components to counteract cisplatin resistance by diminishing MALAT1 expression. These nanoparticles were characterized, and the impact of this targeted carrier was evaluated on AGS gastric cancer cell growth, migration, viability, and the expression of lncRNA MALAT1. Results Characterization of the nanoparticles The X-ray diffraction (XRD) pattern of Cobalt ferrite nanoparticles XRD spectrum of nanoparticles, by using X-ray diffraction data analysis software (XPert) and comparing the diffraction pattern with the reference pattern, it was determined that there are no impurities in the cobalt ferrite structure in the synthesized samples. As can be seen in Fig. 1a, the observed diffraction pattern from the range of 2θ = 20–80◦ with values of 30.22, 35.50, 43.08, 53.52, 56.90, 62.73, and 75.46 displayed distinct peaks corresponding to lattice planes indexed as (220), (311), (222), (400), (422), (511), (440), and (533) reflections, providing evidence for the presence of a single-phase spinel structure with the Fd-3 m space group, which shows the correct formation of the cubic spinel structure of cobalt ferrite nanoparticles and corresponds to the standard sample (JCPDS card no.22-1086)25. As illustrated in the Fig. 1a, the characteristic peaks are still observable after the coating process of pure cobalt ferrite nanoparticles. The reduction in intensity, attributed to polyethyleneimine and chitosan coatings—both of which are amorphous materials—on the cobalt ferrite nanoparticles, has led to a decrease in the crystallinity of the cubic spinel structure. The persistence of these peaks post-coating indicates that the cubic spinel structure is retained despite the presence of the coatings. This observation confirms the synthesis method employed in this study. Fig. 1Characterization of structural and magnetic properties of synthesized nanoparticles. (a) X-ray diffraction (XRD) patterns of CoFe2O4 nanoparticles obtained using the Xpert program. The peaks are observed at 2θ angles of 30.22°, 35.50°, 43.08°, 53.52°, 56.90°, 62.73°, 70.45°, and 75.46°, corresponding to the crystalline structure of cobalt ferrite. (b) Fourier-transform infrared (FTIR) spectra comparing cobalt ferrite nanoparticles with magnetic nanocomposites, highlighting functional group differences. (c) Magnetic hysteresis loops obtained from vibrating sample magnetometry (VSM), comparing the magnetic properties of the nanocomposite and cobalt ferrite nanoparticles. Characterization of structural and magnetic properties of synthesized nanoparticles. (a) X-ray diffraction (XRD) patterns of CoFe2O4 nanoparticles obtained using the Xpert program. The peaks are observed at 2θ angles of 30.22°, 35.50°, 43.08°, 53.52°, 56.90°, 62.73°, 70.45°, and 75.46°, corresponding to the crystalline structure of cobalt ferrite. (b) Fourier-transform infrared (FTIR) spectra comparing cobalt ferrite nanoparticles with magnetic nanocomposites, highlighting functional group differences. (c) Magnetic hysteresis loops obtained from vibrating sample magnetometry (VSM), comparing the magnetic properties of the nanocomposite and cobalt ferrite nanoparticles. FT-IR spectroscopy of Cobalt ferrite nanocomposite The FTIR spectrum obtained within the range of 500–4000 cm− 1 is illustrated in Fig. 1b, detailing the vibrational frequencies of the sample. Generally, the vibration frequencies are influenced by factors such as bond strength, atomic mass, and molecular geometry26. In the Fig. 1b, the spectra related to the synthesis and functionalized of cobalt ferrite nanoparticle are shown by FT-IR analysis. In relation to spinel structures, the presence of distinct peaks corresponding to the metal-oxygen (M-O) absorption bands in the octahedral and tetrahedral sites serves as confirmation of structure formation. These peaks are specifically observed at the higher-frequency peak around 550 cm-1, indicative of the stretching vibrations of metal-oxygen groups at the tetrahedral positions. Also, the peaks in the range of 550–670 cm-1, related to the stretching vibration of the metal-oxygen bond, confirm the Fe-O and Co-O bonds in the magnetic core of CoFe2O4, which are repeated after coating in all the spectra. The band at 1400–1620 cm− 1 indicates the bending vibration of water molecules attached to nanoparticles. The wide band in the region of 3400 cm− 1 indicates the stretching vibration related to the O-H bond in the water molecule. The specified N-H and C-N peaks indicate the placement of polyethyleneimine on the nanoparticle. In the next step, the appearance of N-H peaks and the peak in the region of 1750 cm− 1 indicates the carboxyl group related to the addition of carboxylated cisplatin on polyethyleneimine. In the last stage, C-O-C and NH functional groups are observed, which belong to the chitosan coating. Magnetic properties of nanocomposite and cobalt ferrite nanoparticles In the analysis conducted with the Vibrating Sample Magnetometer (VSM), an external magnetic field was utilized to align the dipole moments of the nanoparticles in the direction of the applied field, followed by the measurement of the magnetic properties of the sample. Figure 1c shows the comparison of magnetic hysteresis curves of synthesized pure cobalt ferrite nanoparticle (NP1) and coated nanocomposite (NP4). The cobalt ferrite magnetic material, synthesized through the hydrothermal method, exhibits a higher hysteresis curve due to its pure magnetic nature. However, upon functionalization with non-magnetic coatings such as polyethylene imine and chitosan, the magnetic properties of the material diminish, leading to a reduction in saturation magnetization. The application of coatings on cobalt ferrite nanoparticles resulted in a transition from a hard magnetic material to a softer magnetic material. Figure 1c illustrates a knee observed in the VSM curve of the coated cobalt ferrite (NP4), attributed to the two-phase nature and the merging of paramagnetic and ferromagnetic phases, leading to valleys between the curves. Moreover, the intensity of the coercive field for the coated cobalt ferrite underwent alterations due to variations in nanoparticle size and the presence of coatings. These coatings induced modifications in the structure of the magnetic material, impacting the tetrahedral and octahedral positions. Specifically, the cobalt ferrite coating induced a knee at these positions, caused by rearrangements in the iron and cobalt cations’ placements, resulting in changes to the material’s saturation magnetization and coercive field. Importantly, these alterations hold significance for applications involving drug loading and magnetic field conductivity in medical applications of these nanoparticles. High-resolution transmission electron microscopy The dimensions of nanoparticles and their surface characteristics were evaluated through High-Resolution Transmission Electron Microscopy (HRTEM) analysis, as illustrated in Fig. 2a. HRTEM imagery at various magnifications revealed the cubic morphology of the nanoparticles, showcasing an average size below 20 nm with a uniform and occasionally dense distribution. Despite the inherent proclivity of magnetic nanoparticles to aggregate, the presence of protective coatings such as polyethyleneimine and chitosan mitigated aggregation tendencies, resulting in larger particle sizes with reduced aggregation. Following the application of coatings, the particle size exhibited less aggregation, achieving a uniform distribution with an average size below 30 nm, illustrating their potential suitability for biological applications. Furthermore, to assess the crystallinity of both uncoated and coated cobalt ferrite samples, Selected Area Electron Diffraction (SAED) patterns were analyzed. The SAED pattern for coated cobalt ferrite nanoparticles exhibited an arrangement characterized by interconnected concentric circles, indicative of a quasi-amorphous structure. Contrastingly, the SAED pattern for uncoated cobalt ferrite nanoparticles did not exhibit interconnected circles; instead, discrete points were observed within specific circles, confirming their complete crystalline nature. Fig. 2Electron microscopy analysis of synthesized nanoparticles. (a) High-resolution transmission electron microscopy (HRTEM) images revealing the size and surface morphology of pure cobalt ferrite nanoparticles and the coated nanocomposite. (b) Field emission scanning electron microscopy (FESEM) images showing the size and surface morphology of pure cobalt ferrite nanoparticles and the coated nanocomposite at two magnifications: 500 nm and 200 nm. (c) Energy-dispersive X-ray spectroscopy (EDAX) spectrum confirming the elemental composition of the cobalt ferrite-coated nanocomposite. Electron microscopy analysis of synthesized nanoparticles. (a) High-resolution transmission electron microscopy (HRTEM) images revealing the size and surface morphology of pure cobalt ferrite nanoparticles and the coated nanocomposite. (b) Field emission scanning electron microscopy (FESEM) images showing the size and surface morphology of pure cobalt ferrite nanoparticles and the coated nanocomposite at two magnifications: 500 nm and 200 nm. (c) Energy-dispersive X-ray spectroscopy (EDAX) spectrum confirming the elemental composition of the cobalt ferrite-coated nanocomposite. Field emission scanning electron microscopy Utilizing the field emission scanning electron microscope (FESEM) enables a comprehensive analysis of the morphology and dimensions of nanoparticles. Figure 2b exhibits images captured at two magnifications, 500 and 200 nm, depicting the surface characteristics of both synthesized pure cobalt ferrite nanoparticles and a coated magnetically nanocomposite. These micrographs illustrate a consistent and uniform arrangement, showcasing the homogeneous distribution of pure cobalt ferrite nanoparticles (NP1) and the coated nanocomposite (NP4), whose average dimensions measure less than 20 and 30 nm, respectively. Furthermore, the images of the coated nanocomposites highlight the particulate arrangement of cobalt ferrite nanoparticles within a polymer matrix. EDS elemental analysis The results of EDAX elemental analysis spectrum for NP1 (CoFe2O4) and NP4 (CoFe2O4@PEI-Pt(iv)-Ch) are shown in Fig. 2c. In Fig. 2c pertaining to cobalt ferrite nanoparticles (NP1), as observed, the peaks corresponding to Co, Fe, and O are present, confirming the cobalt ferrite structure. The intensity of the iron peaks is higher than that of cobalt, as they are present in the composition in a 2:1 ratio, which is consistent with the spinel structure of cobalt ferrite. Furthermore, based on the elemental analysis data presented in Fig. 2c related to the coated cobalt ferrite nanoparticles (NP4), the EDX spectrum confirms the presence of Co, Fe, and O due to the existence of the cobalt ferrite spinel structure. Additionally, the presence of platinum (Pt) is observed due to the incorporation of cisplatin in the composition, and since it is present in a lower quantity, the intensity of its peak is also lower. The presence of nitrogen (N) is attributed to the amine functional groups in the polyethyleneimine and chitosan coatings, confirming their incorporation into the structure. The presence of carbon(C) is noted due to the addition of the carboxyl functional group to cisplatin, as well as its role as an element commonly found in many nanocomposite materials. The zeta potential and dynamic light scattering analysis To confirm successful surface modification and evaluate colloidal stability, we measured zeta potential at pH 5. This pH level mimics the acidic endosomal environment that nanoparticles encounter after cell uptake. Figure 3a shows that the non-coated CoFe2O4 nanoparticles had a nearly neutral mean zeta potential of -0.18 mV. This result indicates that their surface is close to the isoelectric point. Consequently, there is minimal electrostatic repulsion. Fig. 3Colloidal properties of the nanoparticles before and after coating. (a) Zeta potential histograms at pH 5, indicating a charge reversal from − 0.18 mV (NP1) to + 15.98 mV (NP4), which confirms the presence of the polymer shell. (b) DLS intensity-weighted size distributions, showing the growth in hydrodynamic diameter (D50) from 332.3 nm to 410.8 nm upon coating, while maintaining a narrow size distribution. The blue solid line represents the intensity-weighted differential distribution (qi%), showing the relative frequency of particles at each size. The red dashed line shows the cumulative distribution (Qi%), indicating the percentage of particles smaller than a given diameter. Colloidal properties of the nanoparticles before and after coating. (a) Zeta potential histograms at pH 5, indicating a charge reversal from − 0.18 mV (NP1) to + 15.98 mV (NP4), which confirms the presence of the polymer shell. (b) DLS intensity-weighted size distributions, showing the growth in hydrodynamic diameter (D50) from 332.3 nm to 410.8 nm upon coating, while maintaining a narrow size distribution. The blue solid line represents the intensity-weighted differential distribution (qi%), showing the relative frequency of particles at each size. The red dashed line shows the cumulative distribution (Qi%), indicating the percentage of particles smaller than a given diameter. In contrast, after applying the PEI/Chitosan polymer layer, the mean zeta potential shifted to a positive value of + 15.98 mV (from − 25 to + 43). This notable change in surface charge is due to the protonation of the many amine groups found in the PEI and Chitosan structures at this pH. The positive surface charge shows that the polymer shell successfully encapsulates the magnetic cores. It also creates electrostatic repulsion between the nanoparticles, which improves their colloidal stability. The creation of the core-shell nanostructure was confirmed by Dynamic Light Scattering (DLS), as shown in Fig. 3b. The bare CoFe2O4 nanoparticles had an intensity-weighted median hydrodynamic diameter (D50) of 332.3 nm and a low polydispersity index (PDI) of 0.026. This indicates a highly uniform and monodisperse core population. After being coated with PEI/Chitosan, the D50 increased significantly to 410.8 nm. This change corresponds to the formation of a hydrated polymer shell with an average thickness of about 39.3 nm. Notably, the coated nanoparticles retained a low PDI of 0.031, confirming that the coating process was uniform and did not cause aggregation. Drug loading content Drug loading content was determined using atomic absorption spectroscopy. The total cisplatin concentration was calculated as 53 ± 3 mg/L and the drug loading content was calculated as 5.3 ± 0.3 wt%. shRNA-expression cassette synthesis and gel retardation assay The shRNA-expression cassette was synthesized by two-round PCR. The PCR products of the first and second rounds were expected to be 339 bp and 369 bp. As shown in the Fig. 4a (and Supplementary Fig. S1 online), the PCR products of the first and second rounds were migrated between 300 and 400 bp DNA ladder bands, and the PCR product of the second round was heavier than the PCR product of the first round. The observed PCR bands were compatible with the expected 339 bp and 369 bp PCR bands. To evaluate the loading of DNA cassette-on nanocarrier, a gel retardation assay was performed. NP-CDDP-shRNA complexes were formed by mixing varying weight ratios of NP3 to shRNA expression cassettes from 0:1 to 20:1. As shown in the Fig. 4b (and Supplementary Fig. S2 online), no retarded band was observed when the weight ratio was 20:1, indicating that all shRNA expression cassettes was absorbed by NP3 in these weight ratios. According to the results, weight ratio around 10:1 of NP3 to shRNA expression cassettes was adopted in the following study. Fig. 4Construction and loading of shRNA expression cassette and its uptake by AGS cells. (a) A two-round PCR was performed to construct the shRNA expression cassette. The first round PCR product was 339 bp, which was used as a template for the second PCR to generate the shRNA expression cassette (369 bp). (b) Different ratios of shRNA expression cassette to NP3, including 1:0, 1:20, 1:10, 1:5, and 1:1, from left to right, respectively. At a ratio of 1:0, no amount of NP3 was added, so the PCR product band was observed. In the ratio of 1:1 due to the absorption of some cassettes on NP3, a faint band was observed corresponding to the free shRNA expression cassette. In this way, by increasing the ratio of nanoparticles to cassettes, more absorption took place until all cassettes were absorbed by NP3 (1:20), and no trace of free cassettes was observed on the gel. (c) Fluorescence microscopy was utilized to visualize the cellular uptake of the nanocomposite in a serum-free medium at a magnification of 400×. DNA cassettes were labeled with green fluorescent dye and loaded on NP3, and the resultant nanocomposites were used to treat AGS cells. After 24 h, the nuclei of AGS cells were stained by DAPI, and the images were captured under bright-field, blue, and green filters. Construction and loading of shRNA expression cassette and its uptake by AGS cells. (a) A two-round PCR was performed to construct the shRNA expression cassette. The first round PCR product was 339 bp, which was used as a template for the second PCR to generate the shRNA expression cassette (369 bp). (b) Different ratios of shRNA expression cassette to NP3, including 1:0, 1:20, 1:10, 1:5, and 1:1, from left to right, respectively. At a ratio of 1:0, no amount of NP3 was added, so the PCR product band was observed. In the ratio of 1:1 due to the absorption of some cassettes on NP3, a faint band was observed corresponding to the free shRNA expression cassette. In this way, by increasing the ratio of nanoparticles to cassettes, more absorption took place until all cassettes were absorbed by NP3 (1:20), and no trace of free cassettes was observed on the gel. (c) Fluorescence microscopy was utilized to visualize the cellular uptake of the nanocomposite in a serum-free medium at a magnification of 400×. DNA cassettes were labeled with green fluorescent dye and loaded on NP3, and the resultant nanocomposites were used to treat AGS cells. After 24 h, the nuclei of AGS cells were stained by DAPI, and the images were captured under bright-field, blue, and green filters. Intracellular uptake of nanoparticles To determine whether NP-CDDP-shRNA can be taken up by AGS cells and whether shRNA expression cassettes can be effectively delivered to these cells, uptake was assessed using fluorescence microscopy. The cassettes were labeled by green florescent dye, loaded on NP4, poured on cells, and evaluated by florescent microscope. As shown in the Fig. 4c, the nuclei of cells appeared blue due to DAPI staining. Also, 89 ± 4% of DAPI stained cells exhibited green fluorescence, indicating the successful cellular uptake of the NP-CDDP-shRNA and efficient entry of shRNA expression cassettes into the cells. NP-CDDP-shRNA showed the highest toxicity on AGS cells over other synthesized NPs The cytotoxic impact of the synthesized NPs on the AGS cells was investigated by MTT assay after 24 h of treatment. As shown in the Fig. 5a, NPs with scramble expression cassette (NP-Sc) were not cytotoxic for AGS cells in different concentrations ranging from 0.25 to 2 mg/ml at 24 h. At the same time, NP-CDDP, NP-CDDP-Sc, NP-shRNA, and NP-CDDP-shRNA were cytotoxic over 0.5 mg/ml in a concentration-dependent manner at 24 h. The relative cell viability under NP-CDDP-shRNA treatment was 82 ± 7.33% and 55 ± 6.45% at 1 and 2 mg/ml, respectively. Also, the relative cell viability under NP-CDDP-Sc treatment was 85 ± 7.25% and 78 ± 4.67%, respectively. These data demonstrated that anti-MALAT1 shRNA increase the cytotoxicity of CDDP. Fig. 5The impact of various cobalt ferrite nanoparticles at different concentrations on cell viability and migration. (a) The percentage of cell viability in AGS cells treated with different concentrations of NPs is presented relative to untreated cells (n = 5). (b) AGS cell migration was evaluated by light microscopy (100X) at 12, 24, and 48 h after treatment with NP-CDDP-shRNA at 2 mg/ml concentration. (c) Wound closure in NP-CDDP-shRNA-treated cells and untreated cells is represented as mean ± standard deviation. Data is representative of three independent experiments. Statistical comparison between two groups was performed by student-t test, and comparison among more than two groups was made with the one-way ANOVA test followed by Tukey’s post hoc test (*= p < 0.01, **= p < 0.01, ***=p < 0.001). SD = standard deviation, NP-CDDP: NPs with CDDP, NP-shRNA: NPs with anti-MALAT1 shRNA expression cassette, NP-CDDP-Sc: NPs with both CDDP and scramble expression cassette, NP-CDDP-shRNA: NP with both anti-MALAT1 shRNA expression cassette and CDDP. Scale bar = 100 μm. The impact of various cobalt ferrite nanoparticles at different concentrations on cell viability and migration. (a) The percentage of cell viability in AGS cells treated with different concentrations of NPs is presented relative to untreated cells (n = 5). (b) AGS cell migration was evaluated by light microscopy (100X) at 12, 24, and 48 h after treatment with NP-CDDP-shRNA at 2 mg/ml concentration. (c) Wound closure in NP-CDDP-shRNA-treated cells and untreated cells is represented as mean ± standard deviation. Data is representative of three independent experiments. Statistical comparison between two groups was performed by student-t test, and comparison among more than two groups was made with the one-way ANOVA test followed by Tukey’s post hoc test (*= p < 0.01, **= p < 0.01, ***=p < 0.001). SD = standard deviation, NP-CDDP: NPs with CDDP, NP-shRNA: NPs with anti-MALAT1 shRNA expression cassette, NP-CDDP-Sc: NPs with both CDDP and scramble expression cassette, NP-CDDP-shRNA: NP with both anti-MALAT1 shRNA expression cassette and CDDP. Scale bar = 100 μm. Scratch assay To assess the impact of NP-CDDP-shRNA on cell migration, the scratch assay was conducted, and images were captured at various time points − 0 h, 12 h, 24 h, and 48 h. As shown in the Fig. 5b, the result revealed that wound closure was impaired under NP-CDDP-shRNA-treated cells treatment relative to untreated cells, as images showed at different time intervals. Also, Image J software was used to measure the wound closure area, and data were presented in Fig. 5c. As shown in Fig. 5c, the mean wound closure was 16.5 ± 3.53%, 52.5 ± 4.94%, and 85 ± 5.65% in untreated cells at 12, 24, and 48 h, respectively, whereas the average wound closure in NP-CDDP-shRNA -treated cells was about 5.5 ± 2.12%, 26 ± 4.24%, and 28 ± 4.32% at 12, 24, and 48 h, respectively. NP-CDDP-shRNA increases the activity of caspase 3/7 enzymes in AGS cells Caspase 3/7 are enzymes that are activated during apoptosis, so their activity is a measure of the amount of apoptosis. To investigate if the NP-CDDP-shRNA with a concentration of 2 mg/ml could trigger apoptosis in AGS cells, the activity of caspase 3/7 enzymes was evaluated by calorimetric method 24 h after the treatment. As shown in Fig. 6a, the standard curve was generated to measure the activity of caspase 3/7 enzymes that showed high correlation between absorbance and concentration of enzymes (R2 > 0.99). The effect of NP-CDDP-shRNA was compared with the effects of NPs with scramble cassette (NP-Sc) and positive control agent of the kit. As depicted in Fig. 6b, the average caspase 3/7 activity within cells treated with NP-CDDP-shRNA was 0.741 mU/ml, which was higher than the 0.247 mU/ml in NP-Sc-treated cells (p < 0.01). Also, the average caspase 3/7 activity was 1.35 mU/ml among cells treated with a positive control agent. These data demonstrated that NP-CDDP-shRNA could trigger the apoptosis pathway through the activation of caspase 3/7 enzymes. Fig. 6The effects of NP-CDDP-shRNA on caspase 3/7 enzymes activities. (a) a standard curve for different concentrations of caspase substrate versus OD absorbance in 405 nm was prepared using Kit materials. As a result, the standard curve shows a strong positive correlation between the concentration of caspase enzyme substrate and its absorption. This means that the standard curve can be used to calculate the activity of caspases in treated samples accurately. (b) The diagram shows the activity of caspase 3/7 enzymes at 24 h in treated cells with NP-Sc and NP-CDDP-shRNA at 2 mg/ml concentration and positive control for inducing apoptosis. (c) Comparison of MALAT1 gene expression in untreated cells and cells treated with NP-CDDP-Sc and NP-CDDP-shRNA. All Data represent the mean ± standard deviation of three independent experiments. Statistical comparison between two groups was performed by student-t test, and comparison among more than two groups was made with the one-way ANOVA test followed by Tukey’s post hoc test (**= p < 0.01, ****=p < 0.0001). NP-Sc: NPs with scramble expression cassette, NP-CDDP-Sc: NPs with both CDDP and scramble expression cassette, NP-CDDP-shRNA: NP with both anti-MALAT1 shRNA expression cassette and CDDP, +Ctrl: Positive control for inducing apoptosis. The effects of NP-CDDP-shRNA on caspase 3/7 enzymes activities. (a) a standard curve for different concentrations of caspase substrate versus OD absorbance in 405 nm was prepared using Kit materials. As a result, the standard curve shows a strong positive correlation between the concentration of caspase enzyme substrate and its absorption. This means that the standard curve can be used to calculate the activity of caspases in treated samples accurately. (b) The diagram shows the activity of caspase 3/7 enzymes at 24 h in treated cells with NP-Sc and NP-CDDP-shRNA at 2 mg/ml concentration and positive control for inducing apoptosis. (c) Comparison of MALAT1 gene expression in untreated cells and cells treated with NP-CDDP-Sc and NP-CDDP-shRNA. All Data represent the mean ± standard deviation of three independent experiments. Statistical comparison between two groups was performed by student-t test, and comparison among more than two groups was made with the one-way ANOVA test followed by Tukey’s post hoc test (**= p < 0.01, ****=p < 0.0001). NP-Sc: NPs with scramble expression cassette, NP-CDDP-Sc: NPs with both CDDP and scramble expression cassette, NP-CDDP-shRNA: NP with both anti-MALAT1 shRNA expression cassette and CDDP, +Ctrl: Positive control for inducing apoptosis. Real-time PCR To investigate the effect of NP-CDDP-shRNA on MALAT1 silencing, a real-time PCR reaction was performed 24 h after treatment. The relative expression of MALAT1 in NP-CDDP-shRNA -treated cells was compared with its relative expression in untreated cells and the cells treated with NPs with both CDDP and scramble cassette (NPs-CDDP-Sc). As shown in the Fig. 6c, the MALAT1 expression in cells treated with NPs-CDDP-Sc increased significantly by 15.27-fold compared to the untreated cells. However, the MALAT1 expression increased significantly by 6.26-fold compared to the untreated cells. Thus, the administration of shRNA targeting MALAT1 mitigated the MALAT-1 expression level about 9.01-fold (59% decrease relative to NPs-CDDP-Sc), which may play a role in sensitizing AGS cells to CDDP. Discussion Co-delivery of conventional drugs with siRNAs against key genes in cancer progression through MNPs presents a noteworthy strategy to decrease side effects and overcome drug resistance. Among the various types of magnetic nanoparticles, CoFe2O4 MNPs are particularly suitable for drug delivery and tumor targeting due to their high surface-to-volume ratio and unique anticancer properties27. To the best of our knowledge, this is the first study that utilizes CoFe2O4 MNPs coated with PEI and chitosan for the concurrent delivery of cisplatin prodrug and shRNA-expression cassette against MALAT1 lncRNA as important player in gastric cancer development. The CoFe2O4 MNPs coated with PEI and chitosan have some advantages over NPs with Fe₃O₄ core or MNPs coated with polyethylene glycol (PEG). CoFe2O4 MNPs provide higher magnetic anisotropy and chemical stability than Fe₃O₄, as supported by Anikin et al.‘s study28, enhancing magnetically guided delivery, an important issue in the drug delivery research area. In addition, PEI and chitosan coats in our nanocomposite have advantages over PEG in terms of higher gene transfer efficiency and endosomal escape due to the PEI characteristics29 and easy intracellular release and cellular uptake due to the chitosan layer30. In contrast, PEG has higher biocompatibility, increases half-life of circulation, and reduces immunogenicity of nanoparticles31. In this study, the CoFe2O4 MNPs were synthesized with high purity by hydrothermal method. The XRD data fitted the sample data in MAUD and Xpert software and was compatible with the standard reference card. Our data is supported by Jivanantam et al.’s study32 and Allaedini et al.’s study33, which reported that the diffraction planes (220), (311), (400), (511), and (440) exhibited a cubic spinel structure without impurities which were in excellent agreement with the characteristic peaks of an inverse cubic spinel structure, confirming the crystalline structure of CoFe2O4 nanoparticles. Also, the morphology, distribution, and particle size of both uncoated and coated CoFe2O4, were investigated using FESEM and HRTEM imaging. The results indicated that the average sizes of both uncoated and coated CoFe2O4 MNPs were less than 20 nm and 30 nm, respectively. Additionally, the images clearly demonstrated that in the coated CoFe2O4 MNPs, cobalt ferrite nanoparticles were embedded within a polymer matrix, while the pure nanoparticles exhibited a cubic shape. These results are in line with Nikmanesh et al.’s studies that described the structural, magnetic, and morphological properties of the CoFe2O4 MNPs34,35. Furthermore, this study performed FT-IR analysis at all stages of synthesis, coating, and drug loading. The spectral data effectively illustrated the characteristic functional groups of the nanoparticles, the coatings, and the bonds formed to attach CDDP to the coatings. The peaks observed in the range of 550–670 cm–1, which corresponds to the metal-oxygen bonds, is in line with the Kaur et al.36, and Bektar et al.’s FT-IR data37 who synthesized CoFe2O4 NPs. Also, the addition of PEI coat to the CoFe2O4 NPs was confirmed by the observed peak at 681 cm–1 (N–H bond vibration), 1267 cm–1 (C–N bond vibration), and 1424 cm–1 (C–H bond vibration), which is in line with data reported by Bektar et al.’s study that synthesized CoFe2O4@PEI NPs37. Furthermore, the emergence of new N-H peaks at 3050 cm–1 and 1700 cm–1, along with a C-H peak at 2950 cm–1 and an acid C = O peak at 1750 cm–1 in NP2 provide evidence for the carboxylated CDDP linked to the amin group of PEI, which is similar to FT-IR analysis reported by Lai et al.38. Also, the emergence of a C-O-C peak in the region of 920 cm–1 and an N-H peak in the range of 3000–3500 cm–1 in NP3 provides evidence for coating the nanoparticle with chitosan. These peaks were the same as those of chitosan-coated CoFe2O4 nanoparticles synthesized by Ansari et al.39. The EDAX elemental analysis data in our study showed the presence of Co, Fe, O, Pt, N, and C elements, which provide evidence for CDDP loading on chitosan-coated CoFe2O4 NPs. The loading is attributed to the complexation between cisplatin and the amine groups of the PEI/Chitosan shell40. In addition, the result of DLC analysis for our system was 5.3% further confirms CDDP loading and is comparable to DLC of 6.4% reported by Ibarra et al.41 for their poly(lactic-co-glycolic acid) nanoplatform functionalized with polyvinyl alcohol/chitosan and co-loaded with magnetic nanoparticle and cisplatin. In the present study, the VSM analysis showed that the CoFe2O4 NPs exhibit a saturation magnetization of approximately 60 g/emu. Following the application of the coating, the saturation magnetization decreases to 40 g/emu. This phenomenon can be attributed to the presence of non-magnetic surface layers, which lead to the formation of a non-linear rotary structure, resulting in a reduction of the magnetic moments in the nanoparticles as Briceño et al.42, also reported this phenomenon for coated CoFe2O4 NPs. The zeta potential data showed the successful coating. The shift from − 0.18 mV to + 15.98 mV demonstrates that the nanoparticle surface is covered by the cationic PEI and chitosan molecules, which increase colloidal stability, though the zeta potential of NP-CDDP is between 15 and 30 mV, which is categorized in the class of NPs with limited colloidal stability43. Therefore, other modifications may be needed to increase colloidal stability. Also, the positive surface charge offers major functional advantages, including enhanced cellular uptake44,and endosomal escape, which is a critical step for successful drug and gene delivery45. The DLS analysis showed a significant increase in the hydrodynamic diameter of NP-CDDP, a strong indicator of successful coating and drug encapsulation. The low PDI value of NP-CDDP confirms that the NP-CDDP remained monodisperse and did not aggregate during the loading process, which is acceptable for nanoparticles as drug delivery vehicles46. Also, in the present investigation, the fluorescent microscope analysis showed that coated CoFe2O4 NPs were successful carriers in delivering shRNA-expression cassettes to the AGS cells. The gene delivery feature of coated CoFe2O4 NPs could be due to the presence of PEI, which is reported to be essential for binding and transferring DNA to target cells24. This effect may also be due to the presence of chitosan, as this polymer has the ability to absorb and deliver DNA47. Our data demonstrated that NP-CDDP treatment induce MALAT1 expression at 24 h. This data is supported by Zhang et al.48 who showed that MALAT1 expression increased in CDDP-resistant GC cells. The increase in lncRNA expression in response to chemotherapeutic agents has also been reported for other lncRNAs as well49,50. The upregulation of MALAT1 may be a result of DNA damage response. Indeed, cisplatin can induce the NF-κB signaling pathway and the homologous recombination repair pathway, which result in MALAT1 upregulation51,52. Also, MALAT1 upregulation may be a result of endoplasmic reticulum stress that can be induced by cisplatin53,54. In addition, our data showed that the NP-shRNA decreased the expression of MALAT1 which led to decrease in cell viability and increase in cytotoxicity of CDDP. The cytotoxic effect of MALAT1 downregulation on AGS cells were in line with the Lee et al.’s study55 that showed that MALAT1 downregulation significantly reduced AGS cell viability and induced apoptosis by decreasing the Wnt/β-catenin related genes. Also, Chen et al.56 reported that MALAT-1 silencing inhibited the cell proliferation and migration of GC cell lines via a decrease in the expression of the Epithelial-mesenchymal transition (EMT)-associated markers. Also, we found that NP-CDDP-shRNA exhibits cytotoxic effect against AGS cells at 24-hour in a concentration-dependent manner and this effect is significantly higher than NP-CDDP. Although we did not further investigate how MALAT1 downregulation could reverse CDDP resistance, Xi et al.11 demonstrated that MALAT1 silencing decrease autophagy‑related CDDP resistance through increase in miR‑30b/ATG5. Also, our data showed that the coated CoFe2O4 NPs had no cytotoxic effect on AGS cells, which is supported by Kievit et al.’s study24who demonstrated that chitosan decrease the cytotoxicity of PEI. The non-cytotoxic characteristics of the synthesized coat is especially important as uncoated CoFe2O4 NPs were reported to be cytotoxic on different cells57–63. In the present study, in an attempt to find the mechanism of cell cytotoxicity of NP-CDDP-shRNA on AGS cells, the effect of NP-CCDP-shRNA on cell migration and caspase 3/7 activities were evaluated. Our data showed that NP-CDDP-shRNA significantly inhibit cell migration and induce the caspase 3/7 activities as key mediators of mitochondrial events of apoptosis64. Agents that trigger apoptosis and inhibit the cell migration offer potential therapeutic avenues for cancer treatment as help prevent uncontrolled cell proliferation with minimum damage to healthy tissues65. Although, we did not further investigate how NP-CDDP-shRNA induce apoptosis, the apoptotic effect NP-CDDP-shRNA on AGS cells may be due to CDDP66 or/and downregulation of MALAT167. Notably, the present study has been carried out in vitro. Therefore, the efficacy of this nanocomposite in overcoming barriers that exist in vivo should be considered when interpreting the treatment potential of the NP-CDDP-shRNA. For example, the circulation time of NPs, off-target toxicity, and rate of tumor penetration are key barriers that should be evaluated to ensure the biomedical application of NP-CDDP-shRNA. Several strategies, like PEGylation and ligand targeting, may need to overcome these barriers by decreasing immune clearance and increasing tumor penetration. This investigation also has some limitations that need to be addressed in future research. Firstly, we did not directly evaluate the effect of NP-CDDP-shRNA on cell apoptosis by a specific method like annexin-PI staining or TUNEL assay. Second, the CDDP release kinetics should be evaluated to ensure controlled and sustained drug delivery. Third, this research was performed in vitro, and the therapeutic window for NP-CDDP-shRNA was not explored. Therefore, it is necessary to perform an in vivo study to find out the safety and efficacy of NP-CDDP-shRNA. Conclusion The current investigation illustrated the efficacy of a novel multifunctional nanoparticle system developed to overcome drug resistance in gastric cancer. As a proof-of-concept, our nanoparticle improved CDDP sensitivity in AGS gastric cancer cells by targeting the MALAT1 gene, demonstrated anticancer effects through the reduction of AGS cell viability and migration, and increased caspase 3/7 activity. Nevertheless, it is essential to evaluate our nanoformulation using in vivo testing in tumor xenograft models. Furthermore, tumor-targeted magnetic nanoparticles can be engineered for further selective accumulation in tumors and enhanced therapeutic efficacy through the conjugation of tumor-specific targeting ligands. Subsequent research should concentrate on these aspects to advance treatment strategies for gastric cancer. Materials and methods Materials Chemicals, including Cobalt(II) chloride hexahydrate (CoCl2.6H2O), Iron(III) chloride hexahydrate (FeCl3.6H2O), Sodium Hydroxide (NaOH), Dimethylformamide (DMF), N-Hydroxysuccinimide (NHS), hydrogen peroxide (H2O2) 30%, and N, N′-Dicyclohexylcarbodiimide (DCC) were purchased from Merck (Germany). ~25,000 Da branched Polyethyleneimine (PEI), Chitosan (150–250 kDa), Cisplatin (CCDP) powder, Dimethyl Sulfoxide (DMSO) and Agarose were purchased from Sigma-Aldrich (USA). RPMI-1640 culture media, Fetal bovine serum (FBS), penicillin/streptomycin antibiotics (100X), trypsin(0.025%)/EDTA(0.01%), and the MTT cytotoxicity assay kit were purchased from Bio-Idea (Iran). All culture vessels were obtained from SPL Life Science, South Korea. The pMKO.1 puro p53 plasmid was obtained from the Iranian National Center for Genetic and Biologic Resources, SYBR green master mix 2X was obtained from Ampliqon (Denmark), Pfu master mix, cDNA synthesis kit, DNase I (1 U/µl), DNA safe stain, and cDNA synthesis kit was obtained from Kiagene (Iran). Oligonucleotide primers were purchased from Metabion (Germany). Caspase 3/7 activity assay kit were obtained from Kiazist (Iran). DAPI staining solution and RNA extraction kit was obtained from DENA Zist (Iran). Synthesis of Cobalt ferrite nanoparticles In order to perform biological assays several NPs were synthesized, including NPs conjugated with Pt(IV)-COOH (NP-CDDP), NPs with anti-MALAT1 shRNA expression cassette (NP-shRNA), NPs conjugated with both Pt(IV)-COOH and scramble expression cassette (NP-CDDP-Sc), NP conjugated with both anti-MALAT1 shRNA expression cassette and Pt(IV)-COOH (NP-CDDP-shRNA). Figure 7 presents the step-by-step procedure of CoFe2O4 nanoparticle synthesis with different coats in this study. Fig. 7The step-by-step procedure of CoFe2O4 nanoparticle synthesis with different coats. The step-by-step procedure of CoFe2O4 nanoparticle synthesis with different coats. This study employed a hydrothermal method to synthesize CoFe2O4 nanoparticles (NPs) as previously described68. Briefly, The precursors CoCl2.6H2O (2.38 g, 0.01 mol) and FeCl3.6H2O (5.41 g, 0.02 mol) were dissolved in 26.7 mL of deionized water to achieve a stoichiometric Co: Fe ratio of 1:2. The mixture was stirred vigorously (500 rpm) at room temperature for 10 min to ensure homogeneity. Subsequently, 30 mL solution of NaOH (0.5 molL− 1) was added, while monitoring the pH with a calibrated pH meter until it reached 12 (to promote uniform nucleation and crystallization). The solution was stirred for an additional 30 min to stabilize the precipitate. The mixture was then transferred to a Teflon-lined stainless-steel autoclave (150 mL capacity) and heated at 200 °C for 2 h under autogenous pressure. After natural cooling to room temperature, the black precipitate was collected via magnetic separation, washed three times each with deionized water and ethanol to remove impurities, and dried in a vacuum oven at 80 °C for 3 h. Finally, the cobalt ferrite NPs were dried at a temperature of 80 °C for 3 h, and named NP1. Coating cobalt ferrite nanoparticles with polyethylene Imine (CoFe2O4@PEI) To add functional amin groups to cobalt ferrite NPs as places to react with carboxylated CDDP, the synthesized CoFe2O4 NPs were coated with PEI. To prepare PEI-coated NPs, 0.3 g of CoFe2O4 NPs with 170 µl of PEI (1 g/ml) were poured into a small volumetric flask, and 2.5 ml of double distilled water was added. Then, a small magnet was placed inside the balloon. The balloon was closed and placed on the magnetic stirrer for 24 h at room temperature. After this time, the balloon was removed, and after depositing the substance with a magnet, NPs was washed three times with deionized water. In the end, the resulting coated NPs were placed in an oven at 60 °C for 3 h to dry and form CoFe2O4@PEI, which was named NP2. Carboxylation of cisplatin to bind to PEI The carboxylated CDDP was synthesized as previously described69. In brief, 0.47 g of CDDP was poured into a small volumetric flask, and 7.5 ml of H2O2 was added. A magnet was placed inside the balloon and closed with foil wrapped around it. Then, the balloon was placed on the magnetic stirrer overnight under dark conditions at room temperature. After that, the balloon was placed in a bain-marie at 45 °C for 6 h. The resulting precipitate was washed three times with cold ether and placed in a vacuum oven at 60 °C to form the Pt (IV) prodrug powder, namely diamminedichloridodihydroxidoplatinum(IV) (c, c,t-[Pt(NH3)2Cl2(OH)2] or DHP). The 0.34 g DHP powder was poured into a small volume balloon and placed under a vacuum with nitrogen gas. 1.5 g of succinic anhydride was dissolved in 2.5 ml of DMF and added drop by drop to the balloon containing DHP powder under vacuum. The balloon was placed on a stirrer overnight at 55 °C. Then, cold ether was added to the solution containing DHP and DMF. After a few minutes, a yellow precipitate of Pt(IV)-COOH prodrug of cisplatin (c, c,t-[Pt(NH3)2Cl2(O2CCH2CH2CO2H)2] or DSCP) was observed. The precipitate was separated and placed in a vacuum oven to dry. Preparations of drug loaded nanoparticles 100 mg of NP2, 40 mg of DSCP, 3 mg of NHS, and 10 mg of DCC were poured into a small volumetric flask. 7.5 ml of double distilled water was added, the balloon was closed, and foil was wrapped around it. Then, it was placed on a magnetic stirrer at room temperature overnight. The contents of the flask were first centrifuged at 5000 rpm for 10 min; the precipitate was separated and washed with double distilled water. It was centrifuged again, and the sediment obtained was placed in a vacuum oven for 17 h under a temperature of 50 °C and a pressure of 70 mb to gain CoFe2O4@PEI -Pt (IV), which was named NP3. Coating CoFe2O4@PEI-Pt(iv) with Chitosan 40 mg of NP3 was poured into a small balloon and placed on the stirrer. A magnet and 10 ml of double distilled water were added and placed on the stirrer. 1 mg of NHS and 4 mg of DCC were also added to the balloon. Then, 25 mg of chitosan was separately dissolved in 5 ml of distilled water containing 2% acetic acid. Finally, the dissolved chitosan was added to the balloon containing the NP3, and the balloon was closed to allow the binding reaction to take place for 24 h on the magnetic stirrer. After that, the contents of the balloon were subjected to 2 pulses of 5 s sonication to make the distribution uniform. The sediment was isolated using a magnet and washed three times with double distilled water. Finally, the resulting NPs were dried in a vacuum oven at a temperature of 54 °C, and the powder of CoFe2O4@PEI-Pt(iv)-Ch NPs, which was named NP4, was stored in a refrigerator. Characterization of synthesized nanoparticles To determine the magnetic characteristics and structural properties, the samples were subjected to X-ray diffraction (XRD), Field Emission Scanning Electron Microscopy (FESEM), High Resolution Transmission Electron Microscopy (HRTEM), Fourier Transform Infrared (FTIR), Vibrating sample magnetometry (VSM), and Energy Dispersive X-ray Spectroscopy (EDAX) analyses. X-ray diffraction (XRD) analysis was performed utilizing an XRD diffractometer equipped with a Cu-Kα (λ = 0.154 nm) source (D8 Advance model, Bruker, Germany). The morphology of the samples was ascertained through Field Emission Scanning Electron Microscopy (FESEM) coupled with EDAX equipment for elemental identification. Magnetic measurements were carried out using a superconducting quantum interference magnetometer device (SQUID). The surface morphology and chemical composition were explored via high-resolution transmission electron microscopy (HRTEM). Fourier transform infrared spectroscopy (FTIR) analyses were conducted within the 500–4000 cm− 1 wavenumber range at ambient temperature (4600model, JASCO, Japan). Additionally, the magnetic properties of the samples were investigated using a Vibrating Sample Magnetometer (VSM) under a maximum applied magnetic field of 10 kOe at room temperature. The zeta analyzer (CAD Instrument, France) with electrophoretic light scattering capacity was used to assess zeta potential. Deionized water (viscosity = 0.86 mPa·s; conductivity = 0.041 mS/cm) was used as the dispersion medium. Measurements were made at 25 °C using an electrode voltage of 3.3 V. Using the dynamic light scattering (DLS) instrument (Cilas, France) and a fixed scattering angle of 90°, the hydrodynamic diameter and polydispersity index (PDI) were measured at 25 °C. Estimation of CDDP loading content Atomic absorption spectroscopy (AAS) estimates the CDDP loading efficiency on the synthesized nanocomposite. In brief, 5 mg NP3 was suspended in 5 ml of 0.1 N HCl and stirred for 30 min. Subsequently, the NPs were separated by a magnet, and the supernatant was used to measure platinum content by an atomic absorption spectrophotometer (Analytik Jena, contrAA 700). A standard curve was prepared to determine the platinum content. The percentage of CDDP loading content (wt%) was calculated as follows: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$Drug~loading~content\% =\frac{{Mass~of~drug~loaded~nanoparticle}}{{Mass~of~nanoparticle}} \times 100$$\end{document} Construction of the shRNA-expressing cassette against MALAT1 A DNA cassette containing a U6 promoter and shRNA-expressing sequence was constructed by two-step PCR, as described in a previous study15. The pMKO.1 puro p53 plasmid, which contains a U6 promoter for shRNA expression, was used as a template. The first round of PCR was carried out in a total volume of 25 µl using 12.5 µl Pfu master mix, 100 ng of plasmid, and 200 nM of each following primers: Forward primer (F: 5’-AGCCCTCACTCCTTCTCTAGGC − 3’), which anneal to upstream of U6 promoter on template and a reverse primer composed of some sequences of shRNA gene, which was named R1 (R1: 5’–TGGTAATCTCGAGTTTACCAACCACTCGCTTTCCCTGTGCGGTGTTTCGTCCTTTCC–3’). The PCR was run under the following thermal conditions: initial denaturation at 95 °C for 5 min, followed by 30 cycles of denaturation at 95 °C for 30 s, annealing at 60 °C for 30 s, and extension at 72 °C for 10 s. The PCR product of the first reaction was cleaned up using a PCR clean-up kit, diluted at 1:50, and used as a template for the second round of PCR. The second stage PCR is also performed with the previous forward primer and another reverse Primer (R2: 5’–GAAGCAAAAAACACAGGGAAAGCGAGTGGTTGGTAATCTCGAGTTTACCAACCAC–3’) with the same condition as the first-stage PCR. Also, a scramble shRNA cassette as a negative control for gene silencing was synthesized by the same forward primer and the following reverse primers: R1: 5’–TCTCGAGTTGTAGTTACCAACGAACAAGCCCGGTGTTTCGTCCTTTC and R2: AAAAAGCTTGTTCGTTGGTAACTACATCTCGAGTTGTAGTTACCAACG. Loading of shRNA-expressing cassette and gel retardation assay The shRNA-expressing cassette was loaded onto NP3 via electrostatic adsorption. Briefly, 100 µl of serum-free RPMI-1640 medium and 10 µl of sodium acetate (3 M, pH 5.2) were used to equilibrate 5 µg of the cassette and varying amounts of NP3 independently for 5 min at room temperature. Subsequently, the two components were mixed and incubated for an additional 30 min in the shaker incubator at 30 degrees with 180 rpm to form different weight ratios of DNA and NP3, including 1:1, 5:1, 10:1, 20:1, and 50:1. The resultant CoFe2O4@PEI-Pt(iv)-Ch@Cassette was named NP-CDDP-shRNA. Then, the different ratios of the mixture were loaded on an agarose gel to determine the optimal ratio for DNA cassette loading on the nanocomposite surface. Cell culture AGS gastric cancer cell line was cultured in RPMI-1640 medium supplemented with 10% FBS and 500 µl of penicillin/streptomycin antibiotic. The cells were incubated at 37 °C in an incubator with 5% CO2 and 95% humidity. For cell passaging, the media was discarded, and cells were washed with PBS twice. Subsequently, 1 ml trypsin/EDTA solution was added, and cells were incubated for 5 min at 37 °C. MTT cytotoxicity assay A number of 8 × 103 AGS cells were cultured in each well of a 96-well plate in a volume of 100 µl of RPMI-1640 medium supplemented with 10% FBS. After 24 h, cells were exposed to different treatments, including NP-CDDP-shRNA, NP-CDDP-Sc, NP-shRNA, NP-CDDP, and NP-Sc with concentrations of 0.25, 0.5, 1 and 2 mg/ml for 24 h. Then, the media was replaced with 100 µl fresh RPMI-1640 media. Subsequently, 10 µl of MTT solution (5 mg/mL) was added. The plates were incubated for 4 h at 37 °C. afterwards, 50 µl of DMSO was used to dissolve the formazan crystals. Using an ELISA reader, the optical density (OD) of the wells was read at 570 nm. The cytotoxicity of treatment on cells was expressed relative to the control cells. The MTT assay was performed in three biological replicates with six technical replicates per treatment. Intracellular uptake of nanoparticles 5 × 103 AGS cells were seeded in the 96-well plate in a volume of 100 µl of RPMI-1640 medium supplemented with 10% FBS and incubated overnight. 50 µg of NP-CDDP-shRNA was stained with 1 µl SYBR DNA safe stain in 1 ml PBS for 1 h. SYBR DNA safe stain can only stain double-stranded DNA. Afterward, NPs were washed twice with PBS to discard excessive dye. The medium of each well was replaced with 100 µl of stained NP-CDDP-shRNA at a concentration of 50 µg/ml, and the plate was incubated for 24 h at 37 °C and 5% CO2. Subsequently the media was removed, cells were washed with PBS, and 100 µl of acetone-methanol solution (1:1) was added. The plate was incubated at -20 °C for 20 min. Then, cells were stained with DAPI dye (1 µg/ml) for 10 min. Subsequently, the cells were washed and photographed with a fluorescent inverted microscope (Olympus, Japan). The percentage of cells that uptake NP-CDDP-shRNA relative to DAPI-stained cells was quantified using Image J software (Version 1.54 g). The result is presented as the mean of three experiments ± standard deviation. Scratch assay 7 × 105 cells were seeded in each well of a 6-well plate in a 2 ml volume of culture media, and the plate was placed in an incubator upon formation of monolayered cells with approximately 90% confluence. Then, the culture medium was replaced with a fresh medium, and the cells were treated with a concentration of 2 mg/ml NP-CDDP-shRNA or remained untreated as control cells. 12 h later, the culture medium was removed, and a scratch was made on the bottom of each plate well using the head sampler tip. Then, the cells were gently washed with PBS to remove the detached cells. The culture medium containing 2% serum was added. For 24 h, the migration of cells was photographed at different time intervals, and wound closure was quantified using Image J software (Version 1.54 g). The wound Scratch assay was performed in triplicate. The relative wound closure relative to 0 h was calculated based on the following formula: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$${\text{Wound closure }}\left( \% \right) = \left( {1 - \frac{{{\mathrm{Wound~area~at~time~T}}}}{{{\mathrm{Wound~area~at~time~}}0}}} \right) \times 100$$\end{document} Caspase 3/7 activity assay Caspase 3/7 activity assay was performed according to the manufacturer’s instructions to evaluate if NP-CDDP-shRNA can trigger apoptosis. Briefly, 5 × 105 cells were seeded in each well of a 6-well plate and incubated for 24 h. Then, cells were treated with 2 mg/ml NP-CDDP-shRNA for 24 h or remained untreated as control cells. Furthermore, a positive control that induce Caspase 3/7 activity was used. Subsequently, the media was removed, and cells were trypsinized. 1 ml of RPMI medium was added to each well, and each well’s contents were transferred to a 1.5 ml microtube. The microtubes were centrifuged at 800 rpm for 5 minutes at room temperature. Afterward, the supernatant was discarded. 500 µL of Caspase Lysis Buffer was added to each microtube and incubated for 20 min at 4 °C to lyse the cells. Then, microtubes were centrifuged at 12,000 rpm for 15 min at 4 °C. In separate wells of a 96-well plate, 50 µl of the supernatant of each microtube were poured and 55.5 µl of the working solution of the kit was added. Then, the plate was incubated at 37 °C for 11 h. Subsequently, the plate was read by an ELISA reader (BioteK 800TS, UK) at a wavelength of 405 nm. Also, a standard curve for different concentrations of caspase substrate versus OD absorbance in 405 nm was prepared using Kit materials. Finally, Caspase activity was calculated as follows: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$Caspase~activity=\frac{{M \times 105.5}}{{T \times 50}} \times DF$$\end{document} Where, M is µmol which is obtained from standard curve plot, T is incubated time for each sample in minutes, and DF is dilution Factor. The Caspase 3/7 activity assay was performed in triplicate. RNA extraction and real-time PCR analysis 7 × 105 AGS cells were harvested and seeded in 6-well plates prior to treatment. Following a 24-hour treatment with 2 mg/ml NP-CDDP-shRNA, or NPs with scramble gene, total RNA was extracted according to the manufacturer’s instructions, and the quality and quantity of extracted RNA was determined by agarose gel electrophoresis and spectrophotometry, respectively. cDNA was synthesized according to the instructions of cDNA synthesis kit with 1 µg of RNA template. Real-time PCR reactions were carried out using the Corbett rotor-gene 6000, 2X RealQ Plus 2x Master Mix Green Without ROX (Ampliqon, Denmark), and 10 ng of cDNA template. The sequences of the primers for real-time PCR (RT-PCR) assay, were as follows: Forward primer: 5’-GGATTCCAGGAAGGAGCGAGT-3’ and Reverse primer: 5’-CAACATATTGCCGACCTCACG-3’ for MALAT1 and Forward primer: AGCCTTCCTTCCTGGGCATGG and Reverse: AGCACTGTGTTGGCGTACAGGTC for ACTB. The thermal reaction conditions were as follows: initial denaturation at 95 °C for 15 min, followed by 35 cycles of 95°C for 15 s, 60 °C for 20 s, and 72 °C for 20 s. ACTB was used as a calibrator gene and the fold change of MALAT1 were determined using the 2−∆∆CT method70. Real time PCR was performed in triplicate. Statistical analyses Statistical analyses were carried out utilizing GraphPad Prism software (version 9). Data were expressed as mean values ± standard deviation (SD) derived from three distinct experimental trials. Group comparisons were executed through analysis of variance (ANOVA) accompanied by post-hoc assessments or independent t-tests, as deemed suitable. Statistical significance was established at the p < 0.05 threshold. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1